ABOUT US

Oculis is a global biopharmaceutical company purposefully driven to save sight
and improve eye care with breakthrough innovations.

OCS-01 – First-in-class topical eye drop treatment for DME

One of our most advanced product candidates, OCS-01, has successfully completed a Phase 2 trial in DME (DX-211) with 144 patients providing the first proof-of-concept for a topical drug effect in retinal edema. If approved in DME, it has the potential to provide a new and potentially the FIRST non-invasive option for patients.

 

OCS-01 also successfully completed another Phase 2 trial in Inflammation and Pain following cataract surgery. Following the completion of both Phase 2 trials, an End of Phase 2 meeting was conducted with FDA and the product candidate is now moving into phase III in both indications.

 

OCS-01 has been developed using the OPTIREACH solubilizing nanoparticle (SNP) technology, a proprietary platform that enables the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.

 

Potential indications: DME, Ocular Surgery, CME and Posterior Uveitis

OCS-02 – First-in-class topical anti-TNFα for dry eye disease

OCS-02 is a novel topical anti-TNFα therapy. In Dry Eye Disease (DED), two positive Phase 2 proof of concept (PoC) studies have been conducted with OCS-02 and a surrogate molecule. The Phase 2a PoC, which enrolled 134 patients, successfully demonstrated the effect of OCS-02 on DED symptoms with a good tolerability and safety profile. If approved, OCS-02 has the potential to become the first topical biologic for DED.

 

In addition to DED, OCS-02 also successfully completed a PoC Phase 2a study in Acute Anterior Uveitis (AAU), another eye disease with ocular inflammation. As a result, OCS-02 is moving to phase 2b studies in both indications: DED and as a Steroid-Sparing treatment for Chronic Uveitis.

 

OCS-02 is based on an innovative biologic technology that allows for the development of a small, pharmacologically active, humanized single chain variable fragment antibody (scFv). The lower molecular weight of the fragment relative to the whole antibody allows for the development of a topical formulation with high concentration and the penetration into ocular tissues.

 

Potential indications: DED and Steroid-Sparing treatment for Chronic Uveitis

OCS-05 – A potential disease-modifying treatment for glaucoma

OCS-05 is a first-in-class peptidomimetic small molecule with neuroprotective activity that has shown positive results in animal models of neuroinflammation and neurodegeneration.

 

Its mechanism of action is related to the activation of the trophic factor pathways such as IGF-1 and BDNF. In ophthalmology, this action can protect the nerve axons in conditions where the optic nerve is affected, such as in acute optic neuritis and glaucoma, where the OCS-05 could prevent chronic vision loss.

 

Based on positive preclinical data and results of a phase 1 safety and PK study in healthy volunteers, a phase 2a study was initiated (the ACUITY study) which is currently ongoing in Europe.

 

Potential indications: Acute Optic Neuritis, Glaucoma, Neurotrophic Keratitis and Geographic Atrophy